Biogen says sales will slow but lauds supply

Biogen has warned that sales growth for its biosimilars is likely to slow in the second half of 2018, with pricing pressure projected to outweigh volume growth. Nevertheless, the US-based firm believes that the strength of its supply chain will help it maintain a “competitive advantage”, in an increasingly burgeoning market, as Biogen also eyes introducing one of the first Humira (adalimumab) biosimilars in the fourth quarter.